Your browser doesn't support javascript.
loading
Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy.
Divgi, Chaitanya; Carrasquillo, Jorge A; Meredith, Ruby; Seo, Youngho; Frey, Eric C; Bolch, Wesley E; Zimmerman, Brian E; Akabani, Gamal; Jacobson, Daniel A; Brown, Ben; Davern, Sandra M; Hobbs, Robert F; Humm, John; Moros, Eduardo G; Morse, David; Papineni, Rao; Zanzonico, Pat; Benedict, Stanley H; Sgouros, George.
Afiliação
  • Divgi C; Divgi Consulting, LLC, Philadelphia, Pennsylvania.
  • Carrasquillo JA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Meredith R; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
  • Seo Y; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.
  • Frey EC; Russell H. Morgan Department of Radiology and Radiologic Science, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
  • Bolch WE; J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, Florida.
  • Zimmerman BE; Physical Measurement Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland.
  • Akabani G; Department of Nuclear Engineering, Texas A&M University, College Station, Texas.
  • Jacobson DA; Isotope and Fuel Cycle Technology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee.
  • Brown B; Division of Environmental Genomics and Systems Biology, Lawrence Berkeley National Laboratory, Berkeley, California.
  • Davern SM; Isotope and Fuel Cycle Technology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee.
  • Hobbs RF; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Humm J; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Moros EG; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Morse D; Department of Cancer Physiology and Small Animal Imaging Laboratory, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; Departments of Oncologic Sciences and Physics, University of South Florida, Tampa, Florida.
  • Papineni R; Departments of Molecular and Integrative Physiology and Family Medicine Research Division, University of Kansas Medical Center, Kansas City, Kansas; PACT and Health, Branford, Connecticut; Precision X-Ray Inc, North Branford, Connecticut.
  • Zanzonico P; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Benedict SH; Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, California.
  • Sgouros G; Russell H. Morgan Department of Radiology and Radiologic Science, Johns Hopkins University, School of Medicine, Baltimore, Maryland. Electronic address: gsgouros@jhmi.edu.
Int J Radiat Oncol Biol Phys ; 109(4): 905-912, 2021 03 15.
Article em En | MEDLINE | ID: mdl-33309909
Radiopharmaceutical therapy (RPT) continues to demonstrate tremendous potential in improving the therapeutic gains in radiation therapy by specifically delivering radiation to tumors that can be well assessed in terms of dosimetry and imaging. Dosimetry in external beam radiation therapy is standard practice. This is not the case, however, in RPT. This NRG (acronym formed from the first letter of the 3 original groups: National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group)-National Cancer Institute Working Group review describes some of the challenges to improving RPT. The main priorities for advancing the field include (1) developing and adopting best practice guidelines for incorporating patient-specific dosimetry for RPT that can be used at both large clinics with substantial resources and more modest clinics that have limited resources, (2) establishing and improving strategies for introducing new radiopharmaceuticals for clinical investigation, (3) developing approaches to address the radiophobia that is associated with the administration of radioactivity for cancer therapy, and (4) solving the financial and logistical issues of expertise and training in the developing field of RPT.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article